JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

JNJ

225.07

-1.1%↓

ABT

92.85

+1.8%↑

MDT

82.92

-0.55%↓

A

115.57

+0.14%↑

VEEV

160.16

-0.42%↓

Search

Schrodinger Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

11.73 -0.68

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.69

Max

12.22

Pagrindiniai rodikliai

By Trading Economics

Pajamos

169M

136M

Pardavimai

33M

87M

Pelnas, tenkantis vienai akcijai

-0.18

Pelno marža

155.644

Darbuotojai

850

EBITDA

67M

36M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+54.79% upside

Dividendai

By Dow Jones

Kitas uždarbis

2026-05-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

118M

945M

Ankstesnė atidarymo kaina

12.41

Ankstesnė uždarymo kaina

11.73

Naujienos nuotaikos

By Acuity

7%

93%

136 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Schrodinger Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-27 23:15; UTC

Svarbiausios naujienos

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

2026-04-27 23:08; UTC

Uždarbis
Pagrindinės rinkos jėgos

LendingClub Shares Gain on 1Q Profit, Revenue Beat

2026-04-27 23:58; UTC

Uždarbis

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-27 23:58; UTC

Uždarbis

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

2026-04-27 23:56; UTC

Uždarbis

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

2026-04-27 23:56; UTC

Uždarbis

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

2026-04-27 23:48; UTC

Rinkos pokalbiai

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

2026-04-27 23:42; UTC

Rinkos pokalbiai

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

2026-04-27 23:34; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

2026-04-27 23:30; UTC

Rinkos pokalbiai

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

2026-04-27 23:08; UTC

Rinkos pokalbiai

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

2026-04-27 23:02; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-27 23:02; UTC

Rinkos pokalbiai

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

2026-04-27 22:42; UTC

Rinkos pokalbiai

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

2026-04-27 22:10; UTC

Uždarbis

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

2026-04-27 22:09; UTC

Uždarbis

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

2026-04-27 21:56; UTC

Uždarbis

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

2026-04-27 21:55; UTC

Uždarbis

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

2026-04-27 21:55; UTC

Uždarbis

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

2026-04-27 21:44; UTC

Uždarbis

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

2026-04-27 21:43; UTC

Uždarbis

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

2026-04-27 21:41; UTC

Uždarbis

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

2026-04-27 21:41; UTC

Uždarbis

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

2026-04-27 20:50; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai
Svarbiausios naujienos

Basic Materials Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2026-04-27 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-04-27 20:39; UTC

Uždarbis

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Akcijų palyginimas

Kainos pokytis

Schrodinger Inc Prognozė

Kainos tikslas

By TipRanks

54.79% į viršų

12 mėnesių prognozė

Vidutinis 18.25 USD  54.79%

Aukščiausias 20 USD

Žemiausias 13 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Schrodinger Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

4

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

23.27 / 26.13Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Very Strong Bullish Evidence

Ilgalaikis periodas

Very Strong Bullish Evidence

Rinkos nuotaikos

By Acuity

136 / 348 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
help-icon Live chat